Related Experiment Video
Updated: Jul 14, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Biologic therapeutics in the treatment of psoriasis. Part 2: practical considerations
Richard G Langley1, Aditya K Gupta, Andrea M Cherman
1Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS. richard.langley@dal.ca
Background:
Psoriasis is a chronic inflammatory skin disease principally mediated by activated T cells, which release proinflammatory cytokines with reactive epidermal changes in the skin, producing the characteristic lesions of psoriasis. New research into possible treatment options has been inspired by increased understanding of the pathophysiology of psoriasis and advances in immunology and molecular biology permitting the development of targeted, highly active biologic agents.
Objective:
The aim of this article is to provide practical guidelines for integration of these agents in the management of psoriasis.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drug Therapy
Antianxiety Medications
Bioequivalence: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview